The Future, page-14

Simple overview:

- Lack of awareness has kept volume down
- Previous capital raising sell off keeping price down until it is flushed out
- Efficacy and safety of Xanamen proven in trials so far giving good indicator of trial outcome
- Director of Actinogen also on panel of other Alzheimer's research that had all been canned but Xanamen continues. Hint?
- Market cap for such a momentous and widespread treatment with positive results through stage 2 ridiculously undervalued

My call would be to start getting the word out wherever you can, flushing the very short sellers.

Resistance around the 4.7 - 4.9c mark due to the very short sellers.

Current intermediate results showing a more than likely positive stage 2 trial outcome.

Once that resistance is broken there will be a more than positive spike and then results...bam.